Eyenovia concludes type a meeting with fda related to mydcombi™ nda resubmission

No additional clinical work required; nda resubmission anticipated in q3 2022 no additional clinical work required; nda resubmission anticipated in q3 2022

EYEN Ratings Summary

EYEN Quant Ranking